Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 78605
- Registration Number
- NCT04736420
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 19002
- Registration Number
- NCT04736719
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 5350
- Registration Number
- NCT04735523
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
STOPping Anticoagulation for Isolated or Incidental Subsegmental Pulmonary Embolism
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 1466
- Registration Number
- NCT04727437
- Locations
- 🇬🇧
Surrey & Sussex Healthcare NHS Trust, Redhill, United Kingdom
A Drug Interaction Study of Danicopan
- Conditions
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04709094
- Locations
- 🇺🇸
Clinical Study Site, Tempe, Arizona, United States
NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Malmö University
- Target Recruit Count
- 216
- Registration Number
- NCT04662515
- Locations
- 🇸🇪
Skåne University Hospital, Helsingborg, Sweden
🇸🇪Department of Oral and Maxillofacial Surgery and Oral Medicine, Faculty of Odontology, Malmö University, Malmö, Sweden
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Northern Jiangsu People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04645550
- Locations
- 🇨🇳
Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China
Replication of the RELY Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 78140
- Registration Number
- NCT04593043
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Replication of the ARISTOTLE Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 220518
- Registration Number
- NCT04593030
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 102636
- Registration Number
- NCT04593056
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.